A world-first clinical trial has found that baricitinib, a drug commonly prescribed for rheumatoid arthritis, preserved the pancreatic cells’ ability to produce their own insulin and slowed the progression of type 1 diabetes in those recently diagnosed with the condition. The drug shows promise as the first disease-modifying treatment for type 1 diabetes that can be given as a tablet.Type 1 diabetes occurs when the body’s immune system attacks and destroys the pancreas’ insulin-secreting cells.

一项世界首例临床试验发现，通常用于治疗类风湿性关节炎的药物巴利替尼保留了胰腺细胞产生自身胰岛素的能力，并减缓了最近被诊断出患有这种疾病的1型糖尿病的进展。该药物有望成为第一种可以作为片剂服用的1型糖尿病疾病缓解治疗药物。当人体免疫系统攻击并破坏胰腺的胰岛素分泌细胞时，就会发生1型糖尿病。

However, because the destruction is progressive, there are still a substantial number of cells capable of producing insulin early on in the disease.A world-first clinical trial, led by researchers from the St Vincent’s Institute of Medical Research (SVI) in Melbourne, has shown that an existing drug, commonly prescribed for rheumatoid arthritis, given to newly diagnosed type 1 diabetics protects these still-functional cells, preserving the body’s own insulin production and slowing the progression of the disease.“When type 1 diabetes is first diagnosed, there is a substantial number of insulin-producing cells still present,” said Tom Kay, one of the study’s co-authors.

然而，由于破坏是进行性的，因此仍然有大量细胞能够在疾病早期产生胰岛素。墨尔本圣文森特医学研究所（SVI）的研究人员领导的一项世界首例临床试验表明，给新诊断的1型糖尿病患者服用的一种常用于治疗类风湿性关节炎的现有药物可以保护这些功能正常的细胞，保护人体自身胰岛素的产生，减缓疾病的进展。该研究的合著者之一汤姆·凯（TomKay）说：“当第一次诊断出1型糖尿病时，仍然存在大量产生胰岛素的细胞。”。

“We wanted to see whether we could protect further destruction of these cells by the immune system. We showed that baricitinib is safe and effective at slowing the progression of type 1 diabetes in people who have been recently diagnosed.”In the phase 2 trial, the researchers randomly assigned 91 patients aged 10 to 30 diagnosed with type 1 diabetes during the previous 100 days to receive 4 mg/day of baricitinib or a placebo for 48 weeks.

“我们想看看我们是否可以保护免疫系统对这些细胞的进一步破坏。我们证明，巴利替尼在减缓最近被诊断出的1型糖尿病患者的进展方面是安全有效的。”在2期试验中，研究人员随机分配了91名在过去100天内被诊断为1型糖尿病的10至30岁患者，接受每天4毫克的巴利替尼或安慰剂治疗48周。

Baricitinib blocks the actions of Janus kinase (JAK) enzymes, which control inflammation. It’s approved as a treatment for the autoimmune diseases rheumatoid arthritis and alopecia.

Baricitinib阻断控制炎症的Janus激酶（JAK）酶的作用。它被批准用于治疗自身免疫性疾病类风湿性关节炎和脱发。

Researchers at SVI discover groundbreaking new treatment for type 1 diabetes

SVI的研究人员发现了突破性的1型糖尿病新疗法

Major breakthrough in the treatment of Type 1 diabetes

1型糖尿病治疗的重大突破

Source: SVI

资料来源：SVI